

**RECEIVED  
CENTRAL FAX CENTER**

SEP 06 2007

**Amendments to the claims:**

This listing of claims will replace all prior versions and listings of claims in the present application:

**Listing of claims**

Claim 1. (original) A multi-dosage liquid pharmaceutical formulation of human growth hormone consisting essentially of human growth hormone at a concentration of from about 5 mg/ml to about 100 mg/ml, phenol, an aqueous buffer, a non-ionic surfactant, said pharmaceutical formulation having a tonicity of from about 100 mosm/kg to about 500 mosm/kg, having a pH of from about 6.1 to about 6.3, and being substantially free of an amino acid excipient.

Claim 2. (canceled)

Claim 3. (previously amended) The pharmaceutical formulation according to claim 1, wherein the concentration of human growth hormone is from about 5 mg/ml to 14 mg/ml

Claim 6. (canceled)

Claim 7. (previously amended) The pharmaceutical formulation according to claim 1, wherein the buffer is selected from the group consisting of a phosphate buffer, a citrate buffer, an acetate buffer and a formate buffer.

Claim 8. (previously amended) The pharmaceutical formulation according to claim 1, wherein the aqueous buffer is a phosphate buffer.

Claim 9. (previously amended) The pharmaceutical formulation according to claim 1, wherein the buffer has a concentration of from about 5 mM to about 100 mM.

Claim 10. (canceled)

Claim 11. (previously amended) The pharmaceutical formulation according to claim 1, wherein the buffer is a phosphate buffer having a concentration of about 10 mM.

Claim 12. (previously amended) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is selected from the group consisting of a poloxamer and a polysorbate.

Claim 13. (canceled)

Claim 14. (previously amended) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is poloxamer 188.

Claim 15. (previously amended) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is present at a concentration of from about 0.05 to about 4 mg/ml.

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (canceled)

Claim 19. (canceled)

Claim 20. (canceled)

Claim 21. (canceled)

Claim 22. (previously amended) The pharmaceutical formulation according to claim 1, said pharmaceutical composition being substantially isotonic.

Claim 23. (previously amended) The pharmaceutical formulation according to claim 1, said pharmaceutical composition having a pH of about 6.2.

Claim 24. (canceled)

Claim 25. (previously amended) A kit comprising an injection device and a separate container containing a multi-dosage liquid formulation of human growth hormone according to claim 1.

Claim 26. (new) The pharmaceutical formulation according to claim 2, essentially consisting of  
6.67 mg/ml human growth hormone,  
2.5 mg/ml phenol,  
10 mM sodium phosphate buffer,  
2 mg/ml poloxamer 188,  
and having a pH of 6.2.